Quick Answer
Milk Thistle Liver Enzymes Randomized Trial has evidence relevant to strength of evidence and what the studies can or cannot prove, but conclusions should stay close to the cited sources. One representative finding is: 1 2 1 3 4 5 6 Metabolic dysfunction-associated steatotic liver disease [MASLD; formerly known as non-alcoholic fatty liver disease (NAFLD)] is caused by chronic fat deposition in the liver and is the result of complex interactions involving metabolic dysregulation and insulin resistance ().
Key Takeaways
- 011 2 1 3 4 5 6 Metabolic dysfunction-associated steatotic liver disease [MASLD; formerly known as non-alcoholic fatty liver disease (NAFLD)] is caused by chronic fat deposition in the liver and is the result of complex interactions involving metabolic dysregulation and insulin resistance (). [Messier Helen (2026)]
- 02Some patients with MASLD will have metabolic dysfunction-associated steatohepatitis (MASH) which is characterized by hepatocellular ballooning and lobular inflammation (). [Messier Helen (2026)]
- 03MASLD is associated with the development of cirrhosis, liver failure, liver cancer, and type 2 diabetes (). [Messier Helen (2026)]
- 04Imaging tests, including FibroScan, which estimates the amount of fat and fibrosis present in the liver, are used to look for signs of MASLD (). [Messier Helen (2026)]
The current Migaku evidence database contains 1 reusable source document for Milk Thistle Liver Enzymes Randomized Trial. This answer focuses on strength of evidence and what the studies can or cannot prove.
- 1 2 1 3 4 5 6 Metabolic dysfunction-associated steatotic liver disease [MASLD; formerly known as non-alcoholic fatty liver disease (NAFLD)] is caused by chronic fat deposition in the liver and is the result of complex interactions involving metabolic dysregulation and insulin resistance (). [Messier Helen (2026); evidence level 2]
- Some patients with MASLD will have metabolic dysfunction-associated steatohepatitis (MASH) which is characterized by hepatocellular ballooning and lobular inflammation (). [Messier Helen (2026); evidence level 2]
- MASLD is associated with the development of cirrhosis, liver failure, liver cancer, and type 2 diabetes (). [Messier Helen (2026); evidence level 2]
- Imaging tests, including FibroScan, which estimates the amount of fat and fibrosis present in the liver, are used to look for signs of MASLD (). [Messier Helen (2026); evidence level 2]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources